Statement from Mundipharma on COVID-19

With the recent declaration from the WHO of a ‘pandemic’ in response to the coronavirus (COVID-19) outbreak, Mundipharma is committed to secure business continuity and continue To Move Medicine Forward. To do this, and as part of our robust business succession plans, we have taken steps to ensure that manufacturing, supply and distribution of our diabetes, cancer, autoimmune diseases and pain medicines to patients who need them across Europe will continue without interruption. We are also committed to protecting the health of all employees, partners, suppliers and contractors during this difficult time.

Mundipharma has always embraced flexible working and many of our employees and contractors are equipped with the technology and IT support they need to work effectively from home. For our people in positions that require them to be on-site, such as supply and manufacturing, our site health and safety teams are actively following and acting upon all relevant WHO and national health authority recommendations.

We will continue to monitor the situation and communicate regularly with our customers, partners and employees regarding any significant changes that may arise during this critical time.